Oil prices hold sharp losses with focus on secondary India tariffs
WALTHAM, MA— Repligen Corp (NASDAQ:RGEN), a biotech company currently valued at $8.2 billion, saw Director Hunt Anthony recently execute significant stock sales, according to a recent SEC filing. InvestingPro analysis shows the company maintains a FAIR financial health score despite currently trading at high valuation multiples. On March 17, Anthony sold a total of 26,756 shares of Repligen common stock, valued at approximately $4.08 million. The sales were conducted under a pre-arranged 10(b)5-1 trading plan, with transaction prices ranging from $148.05 to $153.70 per share. The stock currently trades near $145, with analysts setting price targets between $155 and $225.
In addition to the sales, Anthony also exercised stock options to acquire 26,756 shares of common stock at prices between $33.87 and $59.52, totaling approximately $1.46 million. Following these transactions, Anthony’s direct ownership of Repligen shares stands at 136,301 shares.
These transactions were part of a broader strategy, as indicated by the trading plan adopted in December 2024, and reflect the director’s ongoing management of his equity holdings in the company.
In other recent news, Repligen Corporation reported its fourth-quarter 2024 financial results, showing a slight revenue increase to $167.5 million, up 1% from the previous year. The company’s adjusted earnings per share (EPS) were $0.44, a decrease from $0.48 in the fourth quarter of 2023. Repligen also provided guidance for 2025, projecting revenue growth of 10%-14% and an adjusted EPS between $1.67 and $1.76. In terms of strategic moves, Repligen announced the acquisition of a bioprocessing desktop portfolio for $70 million, which is expected to contribute $12 million in sales by 2025. This acquisition aligns with their growth plans and enhances their existing technology portfolio.
Analysts have expressed varied opinions on Repligen’s stock. Evercore ISI initiated coverage with an In Line rating and a $155 price target, noting the company’s potential for market recovery. Leerink Partners maintained an Outperform rating with a $200 target, highlighting the strategic importance of the recent acquisition. Meanwhile, H.C. Wainwright reiterated a Buy rating and set a $180 price target, citing confidence in the company’s financial outlook and recent innovations. Canaccord Genuity raised its price target to $170 while maintaining a Hold rating, reflecting a positive outlook on margin expansion and market recovery potential. These developments indicate a mix of cautious optimism and strategic positioning for Repligen amidst evolving market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.